Search

Your search keyword '"Mirallas O"' showing total 121 results
Start Over Author "Mirallas O"
121 results on '"Mirallas O"'

2. 29O Clinical characterization of long-term survivors in phase I clinical trials

Author

Mirallas, O., primary, Rossi, A., additional, Fernández, E.M., additional, Garcia-Galea, E., additional, Cano, K.S. Vega, additional, Moya, J. Ginard, additional, Calvo, A. Hernando, additional, Pretelli, G., additional, Bardaji, M.J. Lostes, additional, Oberoi, A., additional, Galvao, V., additional, Laimito, K.I. Rojas, additional, Morillo, B. Ortega, additional, Casal, G. Alonso, additional, Izquierdo, S. Aguilar, additional, Braña, I., additional, Dienstmann, R., additional, Villar, M. Vieito, additional, and Garralda, E., additional

Published
2024
Full Text
View/download PDF

3. 93P Evolving landscape of targeted therapies (TT) in early phase clinical trials (EPCT): The RESISTANCE project (360R)

Author

Rossi, A., primary, Braña, I., additional, Villar, M. Vieito, additional, Casal, G. Alonso, additional, Santa Gadea, O. Saavedra, additional, Mirallas, O., additional, Bardaji, M.J. Lostes, additional, Galvao, V., additional, Laimito, K.I. Rojas, additional, Oberoi, A., additional, Pretelli, G., additional, Morillo, B. Ortega, additional, Sanz, M., additional, Izquierdo, S. Aguilar, additional, Raskina, K., additional, Dienstmann, R., additional, Vivancos, A., additional, Tabernero, J., additional, Garralda, E., additional, and Calvo, A. Hernando, additional

Published
2024
Full Text
View/download PDF

4. 99P Molecular correlates and treatment outcomes of patients with brain metastasis included in early phase trials: A single-center retrospective analysis

Author

Pretelli, G., primary, Laimito, K.I. Rojas, additional, Casal, G. Alonso, additional, Bardaji, M.J. Lostes, additional, Calvo, A. Hernando, additional, Galvao, V., additional, Oberoi, A., additional, Morillo, B. Ortega, additional, Mirallas, O., additional, Santa Gadea, O. Saavedra, additional, Manich, C. Saura, additional, Fernandez, M.E. Elez, additional, Ortiz, C., additional, Couselo, E. Muñoz, additional, Braña, I., additional, Galceran, J.C., additional, Felip, E., additional, Garralda, E., additional, and Villar, M. Vieito, additional

Published
2024
Full Text
View/download PDF

5. 115P Longterm prognostic utility of 70-gene signature by clinical and genomic risks, including Ultralow (gUL) risk patients (pts)

Author

Gomez, L. Sanz, primary, Zamora, E., additional, Joval, L., additional, Velez, C. Ortiz, additional, Puy, M. Borrell, additional, Arumi de Dios, M.A., additional, Puerto, D.A. Gomez, additional, Garces, V. Navarro, additional, Rezqallah Aron, M.A., additional, Cano, K.S. Vega, additional, Escrivá-De-Romaní, S., additional, Mirallas, O., additional, Pimentel, I., additional, Lapena, M. Cruellas, additional, Villacampa, G., additional, Oliveira, M., additional, Manich, C. Saura, additional, Pardo, P. Gomez, additional, Cámara, V. Peg, additional, and Bellet-Ezquerra, M., additional

Published
2023
Full Text
View/download PDF

6. 250P Liver Toxicity (LT) in patients (pts) with ER-positive HER2-negative metastatic breast cancer (MBC) treated with first-line Cyclin-Dependent Kinase 4/6 inhibitors (CDKi)

Author

Cano, K.S. Vega, primary, Mascaro, P., additional, Mirallas, O., additional, Filippi-Arriaga, F., additional, Joval, L., additional, Zamora, E., additional, Gomez, L. Sanz, additional, Velez, C. Ortiz, additional, Lapena, M. Cruellas, additional, Arumi de Dios, M.A., additional, Puy, M. Borrell, additional, Esteban, P., additional, Ruiz-Ortega, L., additional, Buch, P.B., additional, Yaringaño, J., additional, Lores, G. Molina, additional, Gomez-Puerto, D., additional, Manich, C. Saura, additional, Riveiro-Barciela, M., additional, and Bellet-Ezquerra, M., additional

Published
2023
Full Text
View/download PDF

7. 43P MDM2 alterations in primary brain tumors: A potential niche for targeted therapy

Author

Puerto, D.A. Gomez, Mirallas, O., Velilla, G., Cerna, J.G. Yaringaño, Ruiz-Pace, F., Gonzalez, A. Hernandez, Valbuena, D.E. López, Gorria, T., Vaz Salgado, M.A., Vinolas, M. Domenech, Sorolla, M. Aguado, Rodriguez, M. Gonzalez, Castro-Henriques Pinto-Machado, M., Garcia, M. Martinez, Dienstmann, R., Pineda, E., Galceran, J. Carles, Balana, C., Sanchez, J.M. Sepulveda, and Villar, M. Vieito

Published
2023
Full Text
View/download PDF

8. 457P Progression-free survival 2 (PFS2) as a surrogate for overall survival in a multicentric real-world data cohort of glioblastoma (GBM).

Author

Cerna, J.G. Yaringaño, Mirallas, O., Puerto, D.A. Gomez, Velilla, G., Garces, V. Navarro, Puga, T. Gorría, Monino, A.M., Vaz-Salgado, M.Á., Lopez-Valbuena, D., Gonzalez, A. Hernandez, Sorolla, M. Aguado, Rodriguez, M. Gonzalez, Martínez-García, M., Galceran, J.C., Balana, C., Villacampa, G., Dienstmann, R., Pineda, E., Sepúlveda, J.M., and Vieito, M.

Subjects
*OVERALL survival, *PROGRESSION-free survival, *GLIOBLASTOMA multiforme
Published
2024
Full Text
View/download PDF

9. 686P Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)

Author

Mirallas, O., primary, Marmolejo Castaneda, D.H., additional, Illescas, D.G., additional, Gómez-Puerto, D., additional, Berché, R., additional, Calvo, A.H., additional, Vieito Villar, M., additional, Lorini, L., additional, Navarro, V., additional, Assaf Pastrana, J.D., additional, Saavedra, O., additional, Alonso, G., additional, Aguilar Izquierdo, S., additional, Bescós, C., additional, Lorente, J., additional, Giralt, J., additional, Dienstmann, R., additional, Garralda, E., additional, Felip, E., additional, and Brana, I., additional

Published
2022
Full Text
View/download PDF

10. 350P Postoperative histopathological, clinical and molecular risk score for patients with colorectal liver metastases

Author

Martin Cullell, B., primary, Virgili Manrique, A.C., additional, Riera, P., additional, Fumagalli, C., additional, Sebio Garcia, A., additional, Mirallas, O., additional, Pelegrin, F., additional, Sánchez-Cabús, S., additional, Molina, V., additional, Gonzalez, A., additional, Szafranska, J., additional, and Paez, D., additional

Published
2022
Full Text
View/download PDF

11. 290P Potential enrichment strategies for next-generation sequencing (NGS) in primary brain cancers (pBCs) in a clinical series according to ESMO scale for clinical actionability of molecular targets (ESCAT)

Author

Mirallas, O., primary, López Valbuena, D.E., additional, Yaringaño, J., additional, Martin Cullell, B., additional, Illescas, D.G., additional, Aguilar Izquierdo, S., additional, Martínez-Sáez, E., additional, Pedrola, A., additional, Vivancos, A., additional, Saoudi Gonzalez, N., additional, Ros Montana, F.J., additional, Gonzalez Rodriguez, M., additional, Dienstmann, R., additional, Mateo, J., additional, Tabernero, J., additional, Garralda, E., additional, Carles Galceran, J., additional, and Vieito Villar, M., additional

Published
2022
Full Text
View/download PDF

12. 126P The HLA I composite score and VHIO immune gene-expression signature (VIGex) as selection tools to explore the tumor microenvironment (TME) in patients (pts) treated with immunotherapy (IT)

Author

Saavedra Santa Gadea, O., primary, Vila Casadesus, M., additional, Mirallas, O., additional, Calvo, A.H., additional, Ros Montana, F.J., additional, Baraibar Argota, I., additional, Suarez Rodriguez, C., additional, Oberoi, A., additional, Morales Barrera, R., additional, Iranzo Gomez, P., additional, Alonso, G., additional, Brana, I., additional, Cabrera Navarro, A., additional, Hernández-Illán, E., additional, Vieito Villar, M., additional, Elez Fernandez, M.E., additional, Gonzalez Rodriguez, M., additional, Felip, E., additional, Garralda, E., additional, and Vivancos, A., additional

Published
2022
Full Text
View/download PDF

15. 223P Tumor whole genome sequencing-based ultrasensitive ctDNA analysis as an early biomarker for clinical outcome in immune checkpoint inhibitor (ICI) phase I clinical trials (Ph1) and a tool for beyond progressive disease by iRECIST

Author

Toledo, R.D.A., García, A.M. Calahorro, Moreno, A.B., Mirallas, O., Galvao, V., Casal, G. Alonso, Vieito, M., Braña, I., Oberoi, A., Bardaji, M.J. Lostes, Keough, K.C., Navarro, F., Jimenez, J., Olano, A. Mel, Nuciforo, P.G., Abbott, C., Pugh, J.L., Chen, R., Boyle, S., and Garralda, E.

Published
2024
Full Text
View/download PDF

17. 1479P Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study

Author

Gallardo Melo, P., Bosma, F., Urueña, A., Garrillo Cepeda, J., Aguilar-Company, J., Tapia, J.C., Serna i Mont-Ros, J., Maciel Bravo, L., Martin Cullell, B., Mirallas, O., Gianella Blanco, C., Salva de Torres, C., Martinez Peralta, S., Aguado Sorolla, M., Alonso Martínez, B., Eremiev, S., Roca, M., Serradell, S., Galceran, J.C., and Gomez Pardo, P.

Published
2024
Full Text
View/download PDF

19. 664P Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)

Author

Lostes Bardaji, M.J., Mel Olano, A., Mirallas, O., Morchón Araujo, D., Pérez Fernandez, S., Raskina, K., Galvao, V., Alonso Casal, G., Oberoi, A., Pretelli, G., Rojas Laimito, K.I., Ortega Morillo, B., Ortiz Velez, C., Muñoz-Couselo, E., Viaplana, C., Vieito, M., Braña, I., Dienstmann, R., Hernando Calvo, A., and Garralda, E.

Published
2024
Full Text
View/download PDF

20. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

Author

Pinato, DJ, Aguilar-Company, J, Ferrante, D, Hanbury, G, Bower, M, Salazar, R, Mirallas, O, Sureda, A, Plaja, A, Cucurull, M, Mesia, R, Townsend, S, Jackson, A, Dalla Pria, A, Newsom-Davis, T, Handford, J, Sita-Lumsden, A, Apthorp, E, Vincenzi, B, Bertuzzi, A, Brunet, J, Lambertini, M, Maluquer, C, Pedrazzoli, P, Biello, F, Sinclair, A, Bawany, S, Khalique, S, Rossi, S, Rogers, L, Murphy, C, Belessiotis, K, Carmona-Garcia, MC, Sharkey, R, Garcia-Illescas, D, Rizzo, G, Perachino, M, Saoudi-Gonzalez, N, Doonga, K, Fox, L, Roldan, E, Gaidano, G, Ruiz-Camps, I, Bruna, R, Patriarca, A, Martinez-Vila, C, Cantini, L, Zambelli, A, Giusti, R, Mazzoni, F, Caliman, E, Santoro, A, Grosso, F, Parisi, A, Queirolo, P, Aujayeb, A, Rimassa, L, Prat, A, Tucci, M, Libertini, M, Grisanti, S, Mukherjee, U, Diamantis, N, Fusco, V, Generali, D, Provenzano, S, Gennari, A, Tabernero, J, and Cortellini, A

Abstract

Background The omicron (B.1.1.529) variant of SARS-CoV-2 is highly transmissible and escapes vaccine-induced immunity. We aimed to describe outcomes due to COVID-19 during the omicron outbreak compared with the prevaccination period and alpha (B.1.1.7) and delta (B.1.617.2) waves in patients with cancer in Europe. Methods In this retrospective analysis of the multicentre OnCovid Registry study, we recruited patients aged 18 years or older with laboratory-confirmed diagnosis of SARS-CoV-2, who had a history of solid or haematological malignancy that was either active or in remission. Patient were recruited from 37 oncology centres from UK, Italy, Spain, France, Belgium, and Germany. Participants were followed up from COVID-19 diagnosis until death or loss to follow-up, while being treated as per standard of care. For this analysis, we excluded data from centres that did not actively enter new data after March 1, 2021 (in France, Germany, and Belgium). We compared measures of COVID-19 morbidity, which were complications from COVID-19, hospitalisation due to COVID-19, and requirement of supplemental oxygen and COVID-19-specific therapies, and COVID-19 mortality across three time periods designated as the prevaccination (Feb 27 to Nov 30, 2020), alpha-delta (Dec 1, 2020, to Dec 14, 2021), and omicron (Dec 15, 2021, to Jan 31, 2022) phases. We assessed all-cause case-fatality rates at 14 days and 28 days after diagnosis of COVID-19 overall and in unvaccinated and fully vaccinated patients and in those who received a booster dose, after adjusting for country of origin, sex, age, comorbidities, tumour type, stage, and status, and receipt of systemic anti-cancer therapy. This study is registered with ClinicalTrials.gov, NCT04393974, and is ongoing. Findings As of Feb 4, 2022 (database lock), the registry included 3820 patients who had been diagnosed with COVID-19 between Feb 27, 2020, and Jan 31, 2022. 3473 patients were eligible for inclusion (1640 [47.4%] were women and 1822 [52.6%] were men, with a median age of 68 years [IQR 57-77]). 2033 (58.5%) of 3473 were diagnosed during the prevaccination phase, 1075 (31.0%) during the alpha-delta phase, and 365 (10.5%) during the omicron phase. Among patients diagnosed during the omicron phase, 113 (33.3%) of 339 were fully vaccinated and 165 (48.7%) were boosted, whereas among those diagnosed during the alpha-delta phase, 152 (16.6%) of 915 were fully vaccinated and 21 (2.3%) were boosted. Compared with patients diagnosed during the prevaccination period, those who were diagnosed during the omicron phase had lower case-fatality rates at 14 days (adjusted odds ratio [OR] 0.32 [95% CI 0.19-0.61) and 28 days (0.34 [0.16-0.79]), complications due to COVID-19 (0.26 [0.17-0.46]), and hospitalisation due to COVID-19 (0.17 [0.09-0.32]), and had less requirements for COVID-19-specific therapy (0.22 [0.15-0.34]) and oxygen therapy (0.24 [0.14-0.43]) than did those diagnosed during the alpha-delta phase. Unvaccinated patients diagnosed during the omicron phase had similar crude case-fatality rates at 14 days (ten [25%] of 40 patients vs 114 [17%] of 656) and at 28 days (11 [27%] of 40 vs 184 [28%] of 656) and similar rates of hospitalisation due to COVID-19 (18 [43%] of 42 vs 266 [41%] of 652) and complications from COVID-19 (13 [31%] of 42 vs 237 [36%] of 659) as those diagnosed during the alpha-delta phase. Interpretation Despite time-dependent improvements in outcomes reported in the omicron phase compared with the earlier phases of the pandemic, patients with cancer remain highly susceptible to SARS-CoV-2 if they are not vaccinated against SARS-CoV-2. Our findings support universal vaccination of patients with cancer as a protective measure against morbidity and mortality from COVID-19. Copyright (C) 2022. Published by Elsevier Ltd. All rights reserved.

Published
2022

21. 1431P Descriptive analysis and prognostic factors of microsatellite instability (MSI) gastric cancer patients (pts) compared to microsatellite stable (MSS) pts in a tertiary hospital

Author

Mirallas, O., primary, López-Valbuena, D., additional, García-Illescas, D., additional, Martin Cullell, B., additional, Rodriguez, N., additional, Gantxegi, A., additional, Marmolejo Castaneda, D.H., additional, Valdivia, A.A., additional, Rezqallah Aron, M.A., additional, Villacampa Javierre, G., additional, Gómez-Puerto, D., additional, Vega, K.S., additional, Molina, G., additional, Salva-Torres, C., additional, Jofre, M., additional, Alsina, M., additional, Castro, S., additional, Tabernero, J., additional, Diez, M., additional, and Macarulla Mercade, T., additional

Published
2021
Full Text
View/download PDF

22. 1724P Prognostic parameters at admission as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts) of a tertiary hospital

Author

Mirallas, O., primary, López-Valbuena, D., additional, Javierre, G. Villacampa, additional, Vega, K.S., additional, Gómez-Puerto, D., additional, Salva-Torres, C., additional, Rezqallah, A., additional, Molina, G., additional, Aguilar-Company, J., additional, Roca, M., additional, Andurell, L., additional, Palmas, F., additional, Fernandez, M.E. Elez, additional, Alonso, A., additional, Gomez-Pardo, P., additional, Serradell, S., additional, Tabernero, J., additional, Felip, E., additional, Peñuelas, A., additional, and Carles, J., additional

Published
2021
Full Text
View/download PDF

23. 1560O Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of cancer patients who recovered from SARS-CoV-2 infection

Author

Cortellini, A., primary, Roldán, E., additional, Garcia, M.C. Carmona, additional, Berardi, R., additional, Sánchez, A., additional, Martinez, C., additional, Parisi, A., additional, Jones, E., additional, Bertulli, R.M., additional, Rizzo, G., additional, Guida, A., additional, Chung, C., additional, Bower, M.D., additional, Betti, M., additional, Vincenzi, B., additional, Mirallas, O., additional, Biello, F., additional, Queirolo, P., additional, Gennari, A., additional, and Pinato, D.J., additional

Published
2021
Full Text
View/download PDF

25. 2144P The PRognostic Oncologic Plantology (PROP) website tool predicts 30-day mortality in hospitalized cancer patients on treatment

Author

Mirallas, O., Cullell, B. Martin, Navarro, V., Pedrola, A., Cano, K.S. Vega, Recuero-Borau, J., Salva, C., Valbuena, D.E. López, Puerto, D.A. Gomez, Beltran, J. Sanz, Hermida, J.M. Ucha, Lores, G. Molina, Roca, M., Saiz, A. Peñuelas, Serradell, S., Tabernero, J., Tormo, S. Servitja, Paez, D., Dienstmann, R., and Galceran, J. Carles

Published
2023
Full Text
View/download PDF

27. 473P Predictive factors for drug-induced liver injury in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line cyclin-dependent kinase 4/6 inhibitors

Author

Cano, K.S. Vega, Javierre, G. Villacampa, Baselga, P. Mascaró, Mirallas, O., Adelantado, E. Zamora, Gomez, L. Sanz, Ortiz, C., Lapena, M. Cruellas, Arumi de Dios, M., Puy, M. Borrell, Filippi-Arriaga, F., Joval, L., Yaringaño, J.G., Martínez-Albaladejo, P., Buch, P.B., Esteban, P., Ruiz-Ortega, L., Manich, C. Saura, Riveiro-Barciela, M., and Ezquerra, M. Bellet

Published
2023
Full Text
View/download PDF

28. 503MO Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights

Author

Mirallas, O., Velilla, G., Ruiz-Pace, F., Yaringaño, J.G., Gorria, T., Gomez-Puerto, D., Martínez, Á., Valbuena, D.E. López, Vaz Salgado, M.A., Gonzalez, A. Hernandez, Sorolla, M. Aguado, Raskina, K., Rodriguez, M. Gonzalez, Garcia, M. Martinez, Galceran, J. Carles, Balana, C., Pineda, E., Dienstmann, R., Sánchez, J.M. Sepúlveda, and Villar, M. Vieito

Published
2023
Full Text
View/download PDF

29. Clinical portrait of the SARS-Cov-2 epidemic in European cancer patients

Author

Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R, Segui E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Maconi A, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Carbo A, Bruna R, Benafif S, Marrari A, Wuerstlein R, Carmona-Garcia MC, Chopra N, Tondini C, Mirallas O, Tovazzi V, Betti M, Provenzano S, Fotia V, Cruz CA, Dalla Pria A, D'Avanzo F, Evans JS, Saoudi-Gonzalez N, Felip E, Galazi M, Garcia-Fructuoso I, Lee AJX, Newsom-Davis T, Patriarca A, Garcia-Illescas D, Reyes R, Dileo P, Sharkey R, Wong YNS, Ferrante D, Marco-Hernandez J, Sureda A, Maluquer C, Ruiz-Camps I, Gaidano G, Rimassa L, Chiudinelli L, Izuzquiza M, Cabirta A, Franchi M, Santoro A, Prat A, Tabernero J, Gennari A, Wellcome Trust, and Cancer Treatment & Research Trust

Subjects
1112 Oncology and Carcinogenesis
Abstract

The SARS-Cov-2 pandemic significantly impacted on oncology practice across the globe. There is uncertainty as to the contribution of patients' demographics and oncological features on severity and mortality from Covid-19 and little guidance as to the role of anti-cancer and anti-Covid-19 therapy in this population. In a multi-center study of 890 cancer patients with confirmed Covid-19 we demonstrated a worsening gradient of mortality from breast cancer to haematological malignancies and showed that male gender, older age, and number of co-morbidities identifies a subset of patients with significantly worse mortality rates from Covid-19. Provision of chemotherapy, targeted therapy and immunotherapy did not worsen mortality. Exposure to antimalarials was associated with improved mortality rates independent of baseline prognostic factors. This study highlights the clinical utility of demographic factors for individualized risk-stratification of patients and support further research into emerging anti-Covid-19 therapeutics in SARS-Cov-2 infected cancer patients.

Published
2020

32. 318O Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients

Author

Pinato, D.J., primary, Zambelli, A., additional, Bertuzzi, A., additional, Marrari, A., additional, Saoudi-Gonzalez, N., additional, Mirallas, O., additional, Galazi, M., additional, Generali, D., additional, Grisanti, S., additional, Tondini, C., additional, Prat, A., additional, Tabernero, J., additional, Mesia, R., additional, Salazar, R., additional, Sureda, A., additional, Franchi, M., additional, Chiudinelli, L., additional, Illescas, D.G., additional, Libertini, M., additional, and Gennari, A., additional

Published
2020
Full Text
View/download PDF

33. 1858P Role of depression and quality of life (QOL) status as predictors of hospital length of stay (HLOS) and overall survival (OS) in hospitalized oncologic patients (pts)

Author

Mirallas, O., primary, López Valbuena, D.E., additional, Rezqallah Aron, M.A., additional, Molina, G., additional, Vega, S., additional, Gómez-Puerto, D., additional, Villacampa Javierre, G., additional, Andurell, L., additional, Palmas, F., additional, Burgos, R., additional, Rodriguez, K., additional, Moreno, I., additional, Delgado Heredia, M.J., additional, Roca, M., additional, Dienstmann, R., additional, Alonso, A., additional, Serradell, S., additional, and Carles, J., additional

Published
2020
Full Text
View/download PDF

34. 938P Nutritional status (NS) as a strong predictor for immunotherapy (IT) outcome in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)

Author

Hernando-Calvo, A., primary, Mirallas, O., additional, Marmolejo Castaneda, D.H., additional, Vieito, M., additional, Saavedra Santa Gadea, O., additional, Gardeazabal, I., additional, Villacampa Javierre, G., additional, Aguilar, S., additional, Martin Liberal, J., additional, Bescós, C., additional, Lorente, J., additional, Giralt, J., additional, Benavente, S., additional, Fuentes, J.F., additional, Temprana-Salvador, J., additional, Alberola, M., additional, Dienstmann, R., additional, Garralda, E., additional, Felip, E., additional, and Braña, I., additional

Published
2020
Full Text
View/download PDF

35. 1729P Influence of recent administration and type of oncological treatment (T) in survival of oncological patients (p) with COVID-19: Experience of Vall d’Hebron University Hospital

Author

García-Illescas, D., primary, Saoudi Gonzalez, N., additional, Mirallas, O., additional, Aguilar-Company, J., additional, Ruiz-Camps, I., additional, Garcia-Alvarez, A., additional, Lostes Bardaji, M.J., additional, Valdivia, A., additional, Marmolejo Castaneda, D.H., additional, Rezqallah Aron, M.A., additional, López Valbuena, D.E., additional, Felip, E., additional, Carles, J., additional, and Tabernero, J., additional

Published
2020
Full Text
View/download PDF

36. 1681P First results of the COCO study: COVID-19 outcomes in patients with cancer

Author

Seguí, E., primary, García de Herreros, M., additional, Auclin, E., additional, Mirallas, O., additional, Casadevall, D., additional, Rodriguez, M., additional, Epaillard, N., additional, Tagliamento, M., additional, Pilotto, S., additional, López-Castro, R., additional, Mielgo, X., additional, Urbano, C., additional, Pesántez, D., additional, Saoudi, N., additional, Bluthgen, M.V., additional, Masfarré, L., additional, Minatta, J.N., additional, Cruz, C.A., additional, Mezquita, L., additional, and Prat, A., additional

Published
2020
Full Text
View/download PDF

37. 1713P Active smoking and severity of COVID-19 infection in cancer patients

Author

Marta, G.D.H., primary, Auclin, E., additional, Saoudi Gonzalez, N., additional, Casadevall Aguilar, D., additional, Rodriguez Castells, M., additional, Epaillard, N., additional, Tagliamento, M., additional, Pilotto, S., additional, López-Castro, R., additional, Mielgo Rubio, X., additional, Urbano Centella, C., additional, Pineda, E., additional, Laia, F.M., additional, Mirallas, O., additional, Bluthgen, M.V., additional, Masfarré, L., additional, Minatta, J.N., additional, Cruz, C.A., additional, Prat, A., additional, and Mezquita, L., additional

Published
2020
Full Text
View/download PDF

38. Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt)

Author

Hernando-Calvo, A., primary, Mirallas, O., additional, Marmolejo, D., additional, Felip, E., additional, Javierre, G. Villacampa, additional, Garralda, E., additional, Gutierrez, R., additional, Feliu, B., additional, Martínez, S., additional, Dienstmann, R., additional, and Braña, I., additional

Published
2019
Full Text
View/download PDF

39. Efficacy of Cetuximab Based Chemotherapy after Immunotherapy Treatments (IT) in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Patients (pts)

Author

Hernando-Calvo, A., primary, Mirallas, O., additional, Marmolejo, D., additional, Felip, E., additional, Garralda, E., additional, Javierre, G. Villacampa, additional, Feliu, B., additional, Martínez, S., additional, Gutierrez, R., additional, Dienstmann, R., additional, and Braña, I., additional

Published
2019
Full Text
View/download PDF

40. Molecular subtypes of metastatic (met) gastric cancer (GC) (MoTriGastric): New biomarkers closer to the clinics

Author

Alsina Maqueda, M., primary, Ruiz, F., additional, Landolfi, S., additional, Viaplana, C., additional, Miquel, J.M., additional, Jimenez, J., additional, Diez, M., additional, Gullo, I., additional, Mirallas, O., additional, Tabernero, J., additional, Carneiro, F., additional, Nuciforo, P.G., additional, Vivancos, A., additional, and Dienstmann, R., additional

Published
2019
Full Text
View/download PDF

41. Validation of GAME score risk groups in resected colorectal cancer liver metastases and the prognostic relevance of KRAS, NRAS and BRAF mutation analysis

Author

Martin-Cullell, B., primary, Fumagalli, C., additional, Teres, R., additional, Melo, P Gallardo, additional, Garcia, A Sebio, additional, Manrique, A C Virgili, additional, Mirallas, O., additional, Cabús, S Sánchez, additional, Molina, V., additional, Szafranska, J., additional, and Bravo, D Paez Lopez, additional

Published
2019
Full Text
View/download PDF

46. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Author

Dettorre, Gino M., Dolly, Saoirse, Loizidou, Angela, Chester, John, Jackson, Amanda, Mukherjee, Uma, Zambelli, Alberto, Aguilar Company, Juan, Bower, Mark, Sng, Christopher C. T., Salazar Soler, Ramón, Bertuzzi, Alexia, Brunet, Joan, Mesia, Ricard, Sita-Lumsden, Ailsa, Seguí, Elia, Biello, Federica, Generali, Daniele, Grisanti, Salvatore, Seeva, Pavetha, Rizzo, Gianpiero, Libertini, Michela, Maconi, Antonio, Moss, Charlotte, Russell, Beth, Harbeck, Nadia, Vincenzi, Bruno, Bertulli, Rossella, Ottaviani, Diego, Liñan, Raquel, Marrari, Andrea, Carmona García, M. Carmen, Chopra, Neha, Tondini, Carlo Alberto, Mirallas, Oriol, Tovazzi, Valeria, Fotia, Vittoria, Cruz, Claudia Andrea, Saoudi González, Nadia, Felip, Eudald, Roqué, Ariadna, Lee, Alvin J. X., Newsom-Davis, Tom, García Illescas, David, Reyes, Roxana, Wong, Yien Ning Sophia, Ferrante, Daniela, Scotti, Lorenza, Marco Hernández, Javier, Ruiz Camps, Isabel, Patriarca, Andrea, Rimassa, Lorenza, Chiudinelli, Lorenzo, Franchi, Michela, Santoro, Armando, Prat Aparicio, Aleix, Gennari, Alessandra, Van Hemelrijck, Mieke, Tabernero Caturla, Josep, Diamantis, Nikolaos, Pinato, David J., OnCovid study group, Dettorre, G. M., Dolly, S., Loizidou, A., Chester, J., Jackson, A., Mukherjee, U., Zambelli, A., Aguilar-Company, J., Bower, M., Sng, C. C. T., Salazar, R., Bertuzzi, A., Brunet, J., Mesia, R., Sita-Lumsden, A., Segui, E., Biello, F., Generali, D., Grisanti, S., Seeva, P., Rizzo, G., Libertini, M., Maconi, A., Moss, C., Russell, B., Harbeck, N., Vincenzi, B., Bertulli, R., Ottaviani, D., Linan, R., Marrari, A., Carmen Carmona-Garcia, M., Chopra, N., Tondini, C. A., Mirallas, O., Tovazzi, V., Fotia, V., Cruz, C. A., Saoudi-Gonzalez, N., Felip, E., Roque, A., Lee, A. J. X., Newsom-Davis, T., Garcia-Illescas, D., Reyes, R., Wong, Y. N. S., Ferrante, D., Scotti, L., Marco-Hernandez, J., Ruiz-Camps, I., Patriarca, A., Rimassa, L., Chiudinelli, L., Franchi, M., Santoro, A., Prat, A., Gennari, A., Van Hemelrijck, M., Tabernero, J., Diamantis, N., Pinato, D. J., Wellcome Trust, Institut Català de la Salut, [Dettorre GM] Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. [Dolly S] Medical Oncology, Guy’s and St Thomas’ NHS Foundation Trust (GSTT), London, UK. [Loizidou A] Department of Infectious Diseases, Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium. [Chester J] Medical Oncology, School of Medicine, Cardiff University, Cardiff, UK. Medical Oncology, Velindre Cancer Centre, Cardiff, UK. [Jackson A] Clinical Trials, Velindre Cancer Centre, Cardiff, UK. [Mukherjee U] Medical Oncology, Barts Health NHS Trust, London, UK. [Aguilar-Company J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Mirallas O, Saoudi-Gonzalez N, García-Illescas D] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Ruiz-Camps I] Servei de Malalties Infeccioses, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Male, 0301 basic medicine, Oncology, Cancer Research, Comorbidity, Systemic inflammation, Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores], COVID-19 Testing, 0302 clinical medicine, Neoplasms, Immunotherapy Biomarkers, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], 80 and over, Immunology and Allergy, Medicine, Hypoalbuminemia, Young adult, Càncer, Multivariate Analysi, RC254-282, COVID-19 (Malaltia) - Complicacions, Cancer, Aged, 80 and over, OnCovid study group, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Middle Aged, Prognosis, Inflamació, Systemic Inflammatory Response Syndrome, 030220 oncology & carcinogenesis, Cohort, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Inflammation::Systemic Inflammatory Response Syndrome [DISEASES], Molecular Medicine, Female, medicine.symptom, Life Sciences & Biomedicine, Human, Adult, medicine.medical_specialty, Prognosi, Càncer - Epidemiologia, Immunology, neoplasias [ENFERMEDADES], inflammation mediator, Young Adult, 03 medical and health sciences, Internal medicine, Humans, afecciones patológicas, signos y síntomas::procesos patológicos::inflamación::síndrome de respuesta inflamatoria sistémica [ENFERMEDADES], Aged, Pharmacology, Science & Technology, business.industry, SARS-CoV-2, COVID-19, medicine.disease, inflammation, inflammation mediators, Blood Cell Count, Multivariate Analysis, Neoplasms [DISEASES], Systemic inflammatory response syndrome, 030104 developmental biology, Neoplasm, Lymphocytopenia, business, Other subheadings::Other subheadings::/complications [Other subheadings]
Abstract

Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamació; Mediadors d'inflamació Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflamación; Mediadores de la inflamación Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Inflammation; Inflammation mediators Background Patients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer accrued to the OnCovid study. Methods In a multicenter cohort of SARS-CoV-2-infected patients with cancer in Europe, we evaluated dynamic changes in neutrophil:lymphocyte ratio (NLR); platelet:lymphocyte ratio (PLR); Prognostic Nutritional Index (PNI), renamed the OnCovid Inflammatory Score (OIS); modified Glasgow Prognostic Score (mGPS); and Prognostic Index (PI) in relation to oncological and COVID-19 infection features, testing their prognostic potential in independent training (n=529) and validation (n=542) sets. Results We evaluated 1071 eligible patients, of which 625 (58.3%) were men, and 420 were patients with malignancy in advanced stage (39.2%), most commonly genitourinary (n=216, 20.2%). 844 (78.8%) had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 complication. NLR, OIS, and mGPS worsened at COVID-19 diagnosis compared with pre-COVID-19 measurement (p

Published
2021

48. Hepatic Rupture as the Initial Presentation of an EGFR-Mutated Lung Adenocarcinoma: A Case Report

Author

Oriol Mirallas, Marc Bosch-Schips, Nuria Pardo, Anton Aubanell, Maria Teresa Salcedo-Allende, Ana Callejo, Patricia Iranzo, Josep Tabernero, Enriqueta Felip, Institut Català de la Salut, [Mirallas O, Pardo N, Callejo A, Iranzo P, Tabernero J, Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Bosch-Schips M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Aubanell A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Salcedo-Allende MT] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Adenocarcinoma - Tractament, Cancer Research, Proteïnes quinases - Inhibidors, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Carcinoma::Adenocarcinoma::Adenocarcinoma of Lung [DISEASES], Oncology, neoplasias::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::adenocarcinoma de pulmón [ENFERMEDADES], acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS], Other subheadings::/therapy [Other subheadings], Pulmons - Càncer - Tractament, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS], Otros calificadores::/terapia [Otros calificadores], respiratory tract diseases
Abstract

Metastatic hepatic rupture; Non-small cell lung carcinoma; Tyrosine kinase inhibitor Ruptura hepática metastásica; Carcinoma de pulmón de células no pequeñas; Inhibidor de la tirosina quinasa Ruptura hepàtica metastàtica; Carcinoma de pulmó de cèl·lules no petites; Inhibidor de la tirosina quinasa Hepatic rupture is a rare complication of solid tumor malignancies, notably in lung adenocarcinomas, and carries an extremely poor overall prognosis. Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma predict benefit with tyrosine kinase inhibitors (TKIs). This case report describes a female patient who presented with a metastatic hepatic rupture and was subsequently diagnosed with EGFR-mutated lung adenocarcinoma. The tumor had an impressive response to TKI inhibitor treatment, reversing her extremely poor, short-term prognosis. We believe this unique case sheds light on the treatment management of hepatic ruptures and supports the high response rate seen with TKIs in EGFR-mutated lung cancers, regardless of the patient’s performance status.

Published
2022

49. Combined Treatment with Immunotherapy-Based Strategies for MSS Metastatic Colorectal Cancer

Author

Iosune Baraibar, Oriol Mirallas, Nadia Saoudi, Javier Ros, Francesc Salvà, Josep Tabernero, Elena Élez, Institut Català de la Salut, [Baraibar I, Saoudi N, Ros J, Salvà F, Tabernero J, Élez E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Mirallas O] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Cancer Research, Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], microsatellite stable, terapéutica::terapia biológica::inmunomodulación::inmunoterapia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Immunoteràpia, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], colorectal cancer, Review, Other subheadings::Other subheadings::/drug therapy [Other subheadings], neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias gastrointestinales::neoplasias intestinales::neoplasias colorrectales [ENFERMEDADES], terapéutica::tratamiento combinado [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], cold tumor, mismatch repair-proficiency, digestive system diseases, immune checkpoint inhibitors, Therapeutics::Combined Modality Therapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Còlon - Càncer - Tractament, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Gastrointestinal Neoplasms::Intestinal Neoplasms::Colorectal Neoplasms [DISEASES], Oncology, Recte - Càncer - Tractament, combined treatment, immunotherapy, RC254-282
Abstract

Simple Summary Given that most patients with MSS mCRC do not respond to immunotherapy agents or do not have durable clinical responses, there is an unmet clinical need to obtain predictors of response to immunotherapy and rational immunotherapy-based combination therapies for this entity. In this review, we present the efforts that have been made to date in the clinical setting to develop immunotherapy-based combinations for MSS mCRC and the rationale that lies behind each strategy. Abstract In recent years, deepening knowledge of the complex interactions between the immune system and cancer cells has led to the advent of effective immunotherapies that have revolutionized the therapeutic paradigm of several cancer types. However, colorectal cancer (CRC) is one of the tumor types in which immunotherapy has proven less effective. While there is solid clinical evidence for the therapeutic role of immune checkpoint inhibitors in mismatch repair-deficient (dMMR) and in highly microsatellite instable (MSI-H) metastatic CRC (mCRC), blockade of CTLA-4 or PD-L1/PD-1 as monotherapy has not conferred any major clinical benefit to patients with MMR-proficient (pMMR) or microsatellite stable (MSS) mCRC, reflecting 95% of the CRC population. There thus remains a high unmet medical need for the development of novel immunotherapy approaches for the vast majority of patients with pMMR or MSS/MSI-low (MSI-L) mCRC. Defining the molecular mechanisms for immunogenicity in mCRC and mediating immune resistance in MSS mCRC is needed to develop predictive biomarkers and effective therapeutic combination strategies. Here we review available clinical data from combinatorial therapeutic approaches using immunotherapy-based strategies for MSS mCRC.

Published
2021

50. Aggressive Pituitary Macroadenoma Treated With Capecitabine and Temozolomide Chemotherapy Combination in a Patient With Nelson’s Syndrome: A Case Report

Author

Irene Hernandez, J. Hernando, Oriol Mirallas, Elena Martínez-Sáez, Anas Chaachou, A. Garcia-Alvarez, Betina Biagetti, Francesca Filippi-Arriaga, Anton Aubanell, Jaume Capdevila, Institut Català de la Salut, [Mirallas O, Garcia-Alvarez A, Hernando J, Capdevila J] Servei d’Oncologia Mèdica, Unitat de Tumors Gastrointestinals i Endocrins, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Filippi-Arriaga F] Servei de Farmacologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Hernandez Hernandez I, Biagetti B] Servei d’Endocrinologia i Nutrició, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Aubanell A] Servei de Radiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Chaachou A, Martínez-Saez E] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Hipòfisi - Tumors - Tractament, Adenoma, Male, medicine.medical_specialty, Side effect, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Case Report, Disease, temozolomide, aggressive pituitary tumors, Adenoma - Tractament, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Quimioteràpia combinada, Diseases of the endocrine glands. Clinical endocrinology, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Adenoma [DISEASES], Nelson Syndrome, Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Pituitary Neoplasms::ACTH-Secreting Pituitary Adenoma::Nelson Syndrome [DISEASES], Capecitabine, Endocrinology, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Neoplasm Invasiveness, Pituitary Neoplasms, neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::adenoma [ENFERMEDADES], Adverse effect, Chemotherapy, Temozolomide, Nelson’s syndrome, business.industry, capecitabine, Pituitary tumors, Nelson's syndrome, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Middle Aged, medicine.disease, RC648-665, Surgery, Tumor Burden, Treatment Outcome, neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias hipofisarias::adenoma hipofisario secretor de ACTH::síndrome de Nelson [ENFERMEDADES], Spain, business, medicine.drug
Abstract

Agressive pituitary tumors; Capecitabine; Temozolomide Tumores hipofisarios agresivos; Capecitabina; Temozolomida Tumors hipofisaris agressius; Capecitabina; Temozolomida Nelson’s syndrome is considered a severe side effect that can occur after a total bilateral adrenalectomy in patients with Cushing’s disease. It usually presents with clinical manifestations of an enlarging pituitary tumor including visual and cranial nerve alterations, and if not treated, can cause death through local brain compression or invasion. The first therapeutic option is surgery but in extreme cases of inaccessible or resistant aggressive pituitary tumors; the off-label use of chemotherapy with capecitabine and temozolomide can be considered. However, the use of this treatment is controversial due to adverse events, lack of complete response, and inability to predict results. We present the case of a 48-year-old man diagnosed with Nelson’s syndrome with prolonged partial response and significant clinical benefit to treatment with capecitabine and temozolomide.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results